Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Establishing an International Diabetes Registry Using the DIabetes MONitoring Database (DIAMOND) Electronic Portal (HK012)(CN001)

This study has been completed.
Information provided by (Responsible Party):
Asia Diabetes Foundation Identifier:
First received: January 9, 2011
Last updated: June 26, 2014
Last verified: June 2012

Quality diabetes care requires a team approach and informed decisions of patients and care providers. Several lines of evidence suggests that a protocol-driven care model delivered by trained staff with focus on periodic assessments, reinforcement of patient compliance and attainment of multiple treatment targets reduces risk of cardio-renal complications and early death in type 2 diabetes.

The investigators hypothesize that the use of state of the art information technology to record, manage and analyze the large amount of clinical information generated during various consultation visits will improve the effectiveness and efficiency in implementing these care protocols through decision support and regular feedback to both patients and care team.

Condition Intervention
Other: JADE

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-centre Demonstration Project to Evaluate the Effectiveness and Acceptability of the Joint Asia Diabetes Evaluation (JADE) and DIAbetes MONitoring Database (DIAMOND) Programs in Asian Type 2 Diabetic Patients

Further study details as provided by Asia Diabetes Foundation:

Primary Outcome Measures:
  • Percentage of patients who attain 2 or more of the 'ABC' targets [ Time Frame: 12 months ] [ Designated as safety issue: No ]

    Percentage of patients who attain 2 or more of the following 3 targets:

    • HbA1c <7%
    • BP <130/80 mmHg
    • LDL cholesterol <2.6 mmol/L

Secondary Outcome Measures:
  • New onset of all diabetes-related endpoints [ Time Frame: 12 months ] [ Designated as safety issue: No ]

    This includes;

    • cardiovascular endpoints (acute myocardial infarction, revascularisation procedures, heart failure or unstable angina or arrhythmia requiring hospital admissions, lower extremity amputation or foot ulcers)
    • chronic kidney disease (eGFR<60 ml/min/1.73m2) and end stage renal disease (dialysis and/or eGFR<30 ; ml/min/1.73m2)
    • visual impairment (corrected visual acuity of 20/200 or lower) or eye surgery;
    • cancer
    • any hospitalization due to complications related to diabetes and/or its treatment (such as hypoglycaemic attacks)
    • death

  • Quality of Life [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Frequency of hypoglycaemia (in the last 3 months) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Behavioral changes (in the last 3 months) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    1. Frequency of Self Blood Glucose Monitoring
    2. Adherence to balanced eating
    3. Adherence to regular exercise
    4. Adherence to recommended procedures (e.g. return for blood tests or education classes)

  • Number of hospitalizations, follow up visits by doctors and other care professionals [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Default rates at end of study [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 3586
Study Start Date: January 2010
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: JADE Other: JADE
Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
Active Comparator: DIAMOND Other: DIAMOND
Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.

  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetic patients attending hospitals or affiliated clinics led by PIs of the JADE Program who are living in the area with an intention to have 'regular' follow-up
  • Aged >18 years
  • Patients can have newly diagnosed or established disease, treated with lifestyle or blood glucose lowering drugs including oral agents with or without insulin
  • For newly diagnosed type 2 diabetic patients, their plasma glucose levels should be: a) Fasting plasma glucose (PG) >7.0 mmol/L on 2 or more occasions, and/or b) Random (or post-OGTT 2h) PG >11.1 mmol/L on 2 or more occasions, and/or c) HbA1c >6.5%

Exclusion Criteria:

  • Type 1 diabetes defined as a history of ketosis at diagnosis [acute symptoms with heavy ketonuria (>3+) or ketoacidosis] or continuous requirement of insulin within one year of diagnosis
  • Patients with reduced life expectancy (e.g. less than 6-months) due to recent diagnosis of advanced cancers (e.g. within last 2 years) and other life threatening conditions
  • Patients with a mental condition rendering them unable to understand the nature, scope, and possible consequences of the study
  • Patients actively enrolled in another intervention study
  • Patients who are unwilling to return for regular follow up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01274364

Hong Kong
Asia Diabates Foundation
Shatin, Hong Kong
Sponsors and Collaborators
Asia Diabetes Foundation
Principal Investigator: Juliana Chan, MD Asia Diabetes Foundation
  More Information

Additional Information:
No publications provided

Responsible Party: Asia Diabetes Foundation Identifier: NCT01274364     History of Changes
Other Study ID Numbers: CRE-2010-112
Study First Received: January 9, 2011
Last Updated: June 26, 2014
Health Authority: Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee

Keywords provided by Asia Diabetes Foundation:
Structured Care

Additional relevant MeSH terms:
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases processed this record on March 01, 2015